A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-10

Study Completion Date

2020-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3493269 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3493269 in Healthy Participants

NCT04682106

Healthy

COMPLETED PHASE1

A Safety Study of LY3462817 in Healthy Participants

NCT03715192

Healthy

COMPLETED PHASE1

A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

NCT03841630

Healthy

COMPLETED PHASE1

A Study of LY3461767 in Healthy Participants

NCT04352114

Healthy

COMPLETED PHASE1

A Study of LY3045697 in Healthy Participants

NCT01750853

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo - SC

Participants received Placebo subcutaneously (SC).

Group Type PLACEBO_COMPARATOR

Placebo - SC

Intervention Type DRUG

Administered SC

0.5 mg LY3493269 IV

Participants received 0.5 mg LY3493269 intravenously (IV).

Group Type EXPERIMENTAL

LY3493269 - IV

Intervention Type DRUG

Administered IV

0.15 mg LY3493269 SC

Participants received 0.15 mg LY3493269 SC.

Group Type EXPERIMENTAL

LY3493269 - SC

Intervention Type DRUG

Administered SC

0.5 mg LY3493269 SC

Participants received 0.5 mg LY3493269 SC.

Group Type EXPERIMENTAL

LY3493269 - SC

Intervention Type DRUG

Administered SC

1.5 mg LY3493269 SC

Participants received 1.5 mg LY3493269 SC.

Group Type EXPERIMENTAL

LY3493269 - SC

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3493269 - SC

Administered SC

Intervention Type DRUG

Placebo - SC

Administered SC

Intervention Type DRUG

LY3493269 - IV

Administered IV

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy male or a female who cannot get pregnant
* Have a body mass index (BMI) between 19 and 40 kilograms per square meter (kg/m²), inclusive, at screening
* Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
* Have veins suitable for ease of blood sampling

Exclusion Criteria

* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
* Have previously completed or withdrawn from this study
* Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking during the inpatient stay in the study
* Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
* Have been treated with weight loss medications within 3 months of screening

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes